Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Practice Consolidation Among US Medical Oncologists, 2015-2022.
Milligan M, Erfani P, Orav EJ, Schleicher S, Brooks GA, Lam MB. Milligan M, et al. Among authors: schleicher s. JCO Oncol Pract. 2024 Feb 26:OP2300748. doi: 10.1200/OP.23.00748. Online ahead of print. JCO Oncol Pract. 2024. PMID: 38408291
Comparison of induction agents for rapid sequence intubation in refractory status epilepticus: A single-center retrospective analysis.
Woodward MR, Kardon A, Manners J, Schleicher S, Pergakis MB, Ciryam P, Podell J, Denney Zimmerman W, Galvagno SM Jr, Butt B, Pritchard J, Parikh GY, Gilmore EJ, Badjatia N, Morris NA. Woodward MR, et al. Among authors: schleicher s. Epilepsy Behav Rep. 2024 Jan 8;25:100645. doi: 10.1016/j.ebr.2024.100645. eCollection 2024. Epilepsy Behav Rep. 2024. PMID: 38299124 Free PMC article.
Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled Study.
Schleicher S, Moore A, Rafal E, Gagne-Henley A, Johnson SM, Dhawan S, Chavda R, York JP, Sforzolini B, Holcomb K, Ablon G, Del Rosso J, Dreno B. Schleicher S, et al. Dermatol Ther (Heidelb). 2023 Dec;13(12):3085-3096. doi: 10.1007/s13555-023-01042-7. Epub 2023 Oct 15. Dermatol Ther (Heidelb). 2023. PMID: 37838987 Free PMC article.
Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial.
Guttman-Yassky E, Bahadori L, Brooks L, Clark KL, Grindebacke H, Ho CN, Katial R, Pham TH, Walton C, Datto CJ; HILLIER study group†. Guttman-Yassky E, et al. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):e1211-e1214. doi: 10.1111/jdv.19195. Epub 2023 Jun 12. J Eur Acad Dermatol Venereol. 2023. PMID: 37178404 Clinical Trial. No abstract available.
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Silverberg JI, et al. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. N Engl J Med. 2023. PMID: 36920778 Clinical Trial.
136 results